Loading...
Loading...
Browse all stories on DeepNewz
VisitWhat will be the outcome of the 'Enteromix' clinical trials by the end of 2025?
Successful with expected results • 25%
Partially successful • 25%
Unsuccessful • 25%
Results inconclusive • 25%
Clinical trial results or reports from the Russian Ministry of Health
Russia to Offer Free Personalized mRNA Cancer Vaccine in 2025, Aiming for 75-80% Tumor Reduction
Dec 17, 2024, 09:21 PM
Russia's Ministry of Health has announced the development of a cancer vaccine using mRNA technology, which is set to be distributed free of charge to Russian patients starting in early 2025. The vaccine, which will be personalized for each patient, aims to treat cancer rather than prevent it in the general population. Andrey Kaprin, General Director of the Radiology Medical Research Center of the Russian Ministry of Health, made the announcement, stating that the vaccine will cost the state 300,000 rubles per dose. The vaccine is expected to suppress tumor growth, prevent the spread of cancer, and reduce tumor size by 75-80%. Clinical trials for the oncolytic vaccine 'Enteromix' are underway, with candidates being selected for participation. The vaccine's development is part of a broader global effort, as other countries are also working on similar personalized cancer treatments, with involvement from the Gamaleya National Research Center.
View original story
Less than 25% • 25%
25% to 50% • 25%
51% to 75% • 25%
More than 75% • 25%
Lung cancer • 25%
Breast cancer • 25%
Colorectal cancer • 25%
Other • 25%
Breast Cancer • 25%
Lung Cancer • 25%
Colorectal Cancer • 25%
Other • 25%
Complete Response • 25%
Partial Response • 25%
Stable Disease • 25%
Progressive Disease • 25%
More than 10 countries • 25%
None • 25%
1 to 5 countries • 25%
6 to 10 countries • 25%
Manufacturing issues • 25%
Regulatory hurdles • 25%
Supply chain disruptions • 25%
Other • 25%
Positive results with MRD-negative CR • 25%
Mixed results • 25%
Negative results • 25%
Trial discontinued • 25%
50,001 to 100,000 • 25%
More than 100,000 • 25%
Less than 10,000 • 25%
10,000 to 50,000 • 25%